NorthWest Biotherapeutics Inc (NWBO)

[Basin Street Blues]

Lilly: Donanemab Met Primary Endpoint in Alzheimer’s Phase 2
By Elizabeth Rembert
(Bloomberg) -- Eli Lilly & Co.’s donanemab, an investigational antibody targeting a modified form of beta amyloid, met its primary endpoint in a Phase 2 trial of patients with early symptomatic Alzheimer’s disease, the company reported in a press release.
Treatment met primary endpoint of change from baseline to 76 weeks by slowing cognition and daily function decline by 32% relative to placebo
Did not reach nominal statistical significance on every secondary endpoint measuring cognition and function compared to placebo
Safety profile was consistent with Phase 1 data
Lilly plans to meet with regulators to discuss results and assess next steps
To view the source of this information click here